Expression and clinical significance of HIF-1α and OPN in esophageal cancer tissues

Abstract

Abstract:Objective To discuss the expression and clinical significance of hypoxia-inducible factor-1α (HIF-1α) and osteopontin (OPN) in esophageal cancer tissues. Methods A total of 100 patients with esophageal cancer in Enshi Tujia and Miao Autonomous Prefecture Central Hospital of Hubei Province from January 2015 to January 2017 were selected. The expressions of HIF-1α and OPN in esophageal cancer and adjacent tissues were detected by immunohistochemistry. The relationships between HIF-1α and OPN expressions and clinical pathological characteristics of esophageal cancer patients, as well as the correlation between them were analyzed. Results The positive rates of HIF-1α and OPN expression in esophageal cancer tissues were 70.00% (70/100) and 64.00% (64/100), which were significantly higher than the 14.00% (14/100) and 8.00% (8/100) in adjacent tissues, and the differences were statistically significant (χ²=64.368,P<0.001;χ²=68.056,P<0.001). The expression of HIF-1α was correlated with TNM stage, depth of invasion and lymph node metastasis (χ²=30.159,P<0.001;χ²=17.493,P<0.001;χ²=16.357,P<0.001), but it was not correlated with sex, age, tumor diameter and differentiation (allP>0.05). The expression of OPN was correlated with TNM stage, depth of invasion and lymph node metastasis (χ²=12.558,P=0.002;χ²=15.395,P<0.001;χ²=17.056,P<0.001), but it was not correlated with sex, age, tumor diameter and differentiation (allP>0.05). There was the positive correlation between HIF-1α and OPN expression in esophageal cancer tissues (χ²=61.144,P<0.001,C=0.616). The 2-year survival rates of HIF-1α and OPN positive patients in esophageal cancer tissues were 51.43% and 50.00% respectively, which were significantly lower than those of HIF-1α and OPN negative patients (80.00% and 77.78%), and the differences were statistically significant (χ²=7.143,P=0.008;χ²=7.407,P=0.006). Conclusion HIF-1α and OPN are highly expressed in esophageal cancer tissues, and their high expression may be related to poor survival prognosis of esophageal cancer.

Key words:Esophageal neoplasms,Hypoxia-inducible factor 1, alpha subunit,Osteopontin,Prognosis

Wang Miao, Liu Peijun. Expression and clinical significance of HIF-1α and OPN in esophageal cancer tissues[J]. Journal of International Oncology, 2019, 46(8): 466-470.

References

［1］ Ohnuma H, Sato Y, Hirakawa M, et al. A phase 1/2 study of definitive chemoradiation therapy using docetaxel, nedapla- tin, and 5-Fluorouracil (DNF-R) for esophageal cancer［J］. Int J Radiat Oncol Biol Phys, 2015, 93(2): 382-390. DOI: 10.1016/j.ijrobp.2015.05.041. ［2］李硕果, 姚俊, 高社干. STAT3和HIF-1α在食管癌中的表达及临床意义［J］. 实用医学杂志, 2015, 31(7): 1111-1113. DOI: 10.3969/j.issn.1006-5725.2015.07.021. ［3］刘广珍. 食管癌组织中OPN和CD44v6蛋白的表达及其临床意义［J］. 徐州医学院学报, 2015, 35(11): 749-751. ［4］ Hossain MB Anam MT, Ishika A, Hossain MB, et al. A meta-analysis of hypoxia inducible factor 1-alpha (HIF1A) gene polymorphisms: association with cancers［J］. Biomark Res Oceans, 2015, 3: 29. DOI: 10.1186/s40364-015-0054-z. ［5］刘双立, 刘立根, 刘冬红, 等. 骨桥蛋白、神经性-钙粘附素和MMP-9在结直肠癌中的表达及意义［J］. 中华普外科手术学杂志（电子版）, 2016, 10(3): 251-254. DOI: 10.3877/cma.j.issn.1674-3946.2016.03.024. ［6］王兆坚, 陆海军, 丁晓, 等. 外周血miR-145表达在食管癌放疗近期疗效评价中的意义［J］. 国际肿瘤学杂志, 2017, 44(10): 731-735. DOI: 10.3760/cma.j.issn.1673-422X.2017.10.003. ［7］胥凯凯, 樊佳奇, 田锋, 等. 食管鳞癌组织中表皮生长因子受体表达及基因扩增的临床意义［J］. 临床和实验医学杂志, 2017, 16(18): 1803-1807. DOI: 10.3969/j.issn.1671-4695.2017.18.011. ［8］张曲, 徐姣珍, 张弛, 等. Stattic抑制STAT3和HIF-1α途径对食管癌裸鼠移植瘤放射敏感性的影响［J］. 中华放射医学与防护杂志, 2018, 38(11): 815-818. DOI: 10.3760/cma.j.issn.0254-5098.2018.11.003. ［9］ Umezawa R, Takanami K, Kadoya N, et al. Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer-a pilot study［J］. Radiat Oncol, 2015, 10: 96. DOI: 10.1186/s13014-015-0410-z. ［10］马丽, 于淑霞, 秦旭. HIF-1α与HIF-2α在胃癌中的表达及临床意义［J］. 现代肿瘤医学, 2017, 25(22): 3635-3639. DOI: 10.3969/j.issn.1672-4992.2017.22.023. ［11］ Guo Q, Lan F, Yan X, et al. Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1α in non-small cell lung cancer A549 cells［J］. Oncol Lett, 2018, 16(1): 801-808. DOI: 10.3892/ol.2018.8767. ［12］李志锋, 石荣亚, 赵景曼, 等. HIF-1α、OPN及c-Met在胆管癌中的表达及其临床意义［J］. 肿瘤学杂志, 2016, 22(8): 643-647. DOI: 10.11735/j.issn.1671-170X.2016.08.B007. ［13］ Zduniak K, Ziolkowski P, Ahlin C, et al. Nuclear osteopontin-c is a prognostic breast cancer marker［J］. Br J Cancer, 2015, 112(4): 729-738. DOI: 10.1038/bjc.2014.664. ［14］顾磊, 肖婕, 文斐. 骨桥蛋白、淋巴细胞活化基因-3、Dickkopf相关蛋白1在胃癌组织中的表达及与临床病理特征的相关性［J］. 中国临床保健杂志, 2018, 21(5): 648-652. DOI: 10.3969/J.issn.1672-6790.2018.05.021. ［15］ Blirando K, Mintet E, Buard V, et al. Osteopontin knockout does not influence the severity of rectal damage in a preclinical model of radiation proctitis in mice［J］. Dig Dis Sci, 2015, 60(6): 1633-44. DOI: 10.1007/s10620-014-3520-9.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[13]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[14]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[15]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.